Cellicure - Cell-Based Immunotherapy Technologies

Cellicure provides innovative, cell-based immunotherapy technologies, customized treatment regimens and real world solutions to solve the current unmet therapeutic needs created by cancer, infectious diseases, and chronic inflammatory diseases.

Our Technologies

CAR-NK

Cellicure has developed patented CAR-NK technologies that have overcome the many challenges that arise from using NK cells and NK specific CARs for immunotherapy.

csCAR-NK

Cellicure’s complete signaling CAR (csCAR-NK) enhances activation signaling and overcomes the inhibitory signaling barrier, resulting in complete activation of NK cells.

cytokine-free reNK^TM

Cellicure’s cytokine-free renewable NK (reNK^TM) platform enables the long-term renewability of NK cells that does not require continual cytokine stimulation.

Effic NK^TM

Cellicure’s NK expansion system (Effic-NK^TM) simplifies the human NK expansion process, providing higher efficiency and lower cost.

CAR-T

Cellicure’s CAR-T technology provides CAR-T cells with improved persistence abilities, rapidly accelerating immunotherapy efficiency.

nCAR-T^TM Platforms

Cellicure’s nCAR-T^TM platform provides CAR-T cells with higher persistence, improving the immunotherapy efficiency of CAR-T cells.

Pipeline

Explore Our Pipeline